Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00765102Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Sep 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of romidepsin in multiple myeloma (MM), sponsored by Celgene Corporation. Started Sep 2008; status: terminated.
02
Drugs
romidepsin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00765102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00765102.